Ground-Breaking Planned Phase IIB Trial of CAR T Cell AU105 in Glioblastoma

Aurora is planning to apply for Breakthrough Therapy Designation. The Company is planning a Ground-Breaking Randomized High-Powered Phase IIB/III clinical trial in Newly Diagnosed Glioblastoma with AU105.

Revolutionary Planned Phase I/II Trial of CAR Y Cell with Novel Intracranial Catheter

Aurora is currently recruiting for a Phase I/II Trial in Recurrent Glioblastoma using novel intracranial catheter, to bypass the Blood Brain Barrier and deliver CAR T “serial killer” cells locally.